60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

* Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (NCT06207370). The outcome of the interim analysis will be disclosed no later than October 6, 2026. Enrollment will continue in the interim.

60 Degrees is the sponsor of a double-blind, randomized, multisite, placebo-controlled clinical trial entitled “Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis,” which evaluates the efficacy and safety of tafenoquine in treating severe babesiosis in humans. Patients are enrolled at multiple sites in the U.S., including Tufts Medical Center, Rhode Island Hospital, Yale University, Brigham and Women’s Hospital, and Westchester Medical Center.